Euroland announced on Wednesday that it had initiated coverage of DMS shares with a Buy recommendation, praising the medical diagnostics specialist's "international reach".

While acknowledging that the share's stock market performance has been "very turbulent", the analyst is confident about the group's positioning, as well as its short-, medium- and long-term prospects

From the research consultancy's point of view, DMS is at the dawn of a "new page in its history", combining growth with a strong improvement in profitability.

In particular, Euroland highlights the ambitions of the new strategic plan presented in October 2022, which aims to transform the company into a key European player in medical imaging.

Its valuation stands at two euros per share.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.